
|Videos|August 26, 2021
Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
Advertisement
Episodes in this series

Advertisement
Related to this article

A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
3
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
4
Cystatin C and the Future of Kidney Function Assessment
5

